News | December 2, 2024
Devyser achieves Class D IVDR approval for its RHD product
Find out more
News
Devyser at 20: Celebrating two decades of innovation in genetic diagnostics
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoring
Devyser Compact achieves Class III approval in China
Devyser to share data at ASHI 2024 demonstrating its innovations and studies within transplantation
Devyser Diagnostics AB publishes quarterly report for the period April to June 2024
“Devyser continued to report high sales growth in the second quarter. Organic growth compared with...
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.9 million SEK
Devyser wins tender in Sweden for Thalassemia NGS testing worth up to 8.4 million SEK
Devyser announces expanded commercial agreement with Thermo Fisher Scientific for post-transplant monitoring NGS products
Devyser launches updated Y-Chromosomal microdeletion test
Devyser wins all-time high tender for up to 75 MSEK
